Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
about
Targeting SRC in mucinous ovarian carcinoma.Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinomaEstrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.Overcoming platinum resistance in ovarian carcinoma.Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancerChemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublinesSignificance of lymphovascular space invasion in epithelial ovarian cancer.Primary peritoneal adenocarcinoma as content of an incarcerated umbilical hernia: A case-report and review of the literaturePlatelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer Patients
P2860
Q33638051-5CE0E843-B9E5-48E9-8CDA-B9789F312B6FQ34171626-87CE1B7C-B205-43F3-B9A2-F31473929707Q34219967-77D8F7DA-0867-4B0A-AA7E-DF77E02C63EEQ34233273-B87B7609-3906-4545-9BA3-584371DE1748Q34241202-424E17A7-6E71-4DC4-8A77-498DC9CDDE46Q34742974-8C8AEAB6-FF71-4597-B09F-3407069B5B38Q35243396-C27FD780-729F-4C6B-8BBC-D1825898D84FQ35649272-FF147F32-6A99-4D3D-9BDB-6BCC7738BF47Q36530725-C80F6104-1061-474D-8AFE-9CBB5778C077Q36587222-7F05B366-11D3-473E-9B09-8268E504B9DAQ37625369-C6133524-9C05-4954-90DA-EBE11487CADFQ37680702-CB52C90B-7354-4EEF-B85A-8407335FC250Q38787442-0991A031-BC8B-4208-85C0-6B6CFE69A366Q42617692-12EB38C4-950C-464D-89B2-1470DA0217DBQ47965726-5C2F4242-11A4-4DD4-AC8F-7AA4A51C6948Q49196144-1894271F-7F7A-458D-9B32-F4D1357C3229
P2860
Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@en
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@nl
type
label
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@en
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@nl
prefLabel
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@en
Low drug resistance to both pl ...... llopian and peritoneal cancer.
@nl
P2093
P356
P1476
Low drug resistance to both pl ...... allopian and peritoneal cancer
@en
P2093
Dwight D Im
Michele L Eno
Neil B Rosenshein
Virginia K Bond
P304
P356
10.1002/IJC.24654
P50
P577
2009-12-01T00:00:00Z